Todd C Davis Ligand Pharmaceuticals Inc (LGND) insider trading activity

LGND Quotes by TradingView

Todd C Davis is Chief Executive Officer of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 161,467 shares of LGND, which is worth approximately $24.2 Million. The most recent transaction as insider was on Jun 30, 2025, when has been sold 233 shares (Common Stock) at a price of $91.08 per share, resulting in proceeds of $21,221. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 161K
0.14% 3M change
31.26% 12M change
Total Value Held $24.2 Million

Todd C Davis Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 30 2025
BUY
Other acquisition or disposition
$21,221 $91.08 p/Share
233 Added 0.14%
161,467 Common Stock
May 09 2025
BUY
Open market or private purchase
$997,789 $104.92 p/Share
9,510 Added 5.57%
161,234 Common Stock
Mar 04 2025
BUY
Grant, award, or other acquisition
-
21,382 Added 12.35%
151,724 Common Stock
Feb 15 2025
SELL
Payment of exercise price or tax liability
$778,320 $120.0 p/Share
6,486 Reduced 4.74%
130,342 Common Stock
Feb 14 2025
SELL
Payment of exercise price or tax liability
$835,920 $120.0 p/Share
6,966 Reduced 4.84%
136,828 Common Stock
Feb 14 2025
BUY
Grant, award, or other acquisition
-
20,784 Added 12.63%
143,794 Common Stock
Aug 08 2024
BUY
Open market or private purchase
$243,475 $97.39 p/Share
2,500 Added 1.99%
123,010 Common Stock
Jun 28 2024
BUY
Other acquisition or disposition
$21,248 $60.71 p/Share
350 Added 0.29%
120,510 Common Stock
Mar 25 2024
BUY
Exercise of conversion of derivative security
$993,570 $62.04 p/Share
16,015 Added 11.76%
120,160 Common Stock
Feb 27 2024
BUY
Grant, award, or other acquisition
-
32,436 Added 23.75%
104,145 Common Stock
Feb 15 2024
SELL
Payment of exercise price or tax liability
$103,091 $74.65 p/Share
1,381 Reduced 1.89%
71,709 Common Stock
Sep 22 2023
BUY
Open market or private purchase
$237,520 $59.38 p/Share
4,000 Added 5.19%
73,090 Common Stock
Jun 09 2023
SELL
Payment of exercise price or tax liability
$30,979 $73.76 p/Share
420 Reduced 0.6%
69,090 Common Stock
Feb 23 2023
BUY
Grant, award, or other acquisition
-
17,005 Added 19.82%
68,791 Common Stock
Jun 10 2022
BUY
Grant, award, or other acquisition
-
1,004 Added 1.9%
51,786 Common Stock
Jun 04 2021
BUY
Grant, award, or other acquisition
-
630 Added 1.23%
50,782 Common Stock
Feb 11 2021
BUY
Exercise of conversion of derivative security
$484,681 $195.91 p/Share
2,474 Added 4.7%
50,152 Common Stock
Feb 10 2021
SELL
Open market or private sale
$1,083,391 $213.14 p/Share
5,083 Reduced 9.63%
47,678 Common Stock
Jan 27 2021
BUY
Exercise of conversion of derivative security
$278,756 $113.5 p/Share
2,456 Added 4.45%
52,761 Common Stock

Also insider at

VXRT
Vaxart, Inc. Healthcare
Director
BDSI
BIODELIVERY SCIENCES INTERNATIONAL INC Healthcare
Director
CHRO
Chromocell Therapeutics Corp
Director
PIRS
PIERIS PHARMACEUTICALS, INC. Healthcare
Director
TCD

Todd C Davis

Chief Executive Officer
South San Francisco, CA

Track Institutional and Insider Activities on LGND

Follow LIGAND PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

News

Receive news related to LIGAND PHARMACEUTICALS INC

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on LGND